Singapore International Commercial Court · Decided 29 April 2020
Baker, Michael A (executor of the estate of Chantal Burnison, deceased) v BCS Business Consulting Services Pte Ltd and others
Feedback & support[2020] SGHC(I) 10 · Case no. Suit No 3 of 2018
✱ What happened, in plain English
There is no plain-English summary of this judgment yet.
Ask about this judgment →Grounds of decision
Official text from eLitigation
The parties
- [1]
[1] The plaintiff, Michael Baker (“Baker”), is the executor of the estate of Chantal Burnison (“Chantal” or “the Estate”, as the case may be), who succumbed to cancer on 2 October 2016 in Los Angeles. Baker is a practising attorney in the State of California and was a friend and confidante of Chantal. Chantal, who divorced her husband in 1993, is survived by two daughters, Heika Burnison (“Heika”) born in 1987 and Birka Burnison (“Birka”) born in 1990.
- [2]
[2] The 2nd defendant, Marcus Weber (“Weber”), is a Swiss national who operated out of Zurich until 2002 when he obtained a permit to work in Singapore. Weber became a permanent resident of Singapore in 2003.
- [3]
[3] The 1st defendant, BCS Business Consulting Services Pte Ltd (“BCS”), is a company incorporated in Singapore on 31 March 1999. It was incorporated as BCS Business Commercial Services Pte Ltd with a change of name to its present name on 26 July 2002. Weber is a director and the sole shareholder of BCS. The 3rd defendant, Renslade Holdings Limited (“Renslade (HK)”) is a company incorporated in Hong Kong on 5 November 2007 and Weber is the sole shareholder of Renslade (HK). It is not disputed that Weber in effect owns and controls BCS and Renslade (HK). A reference to “the Defendants” includes a reference to Weber, BCS and/or Renslade (HK) as the context so requires.
- [4]
[4] Baker, as executor of Chantal’s estate, sues the Defendants for breach of fiduciary duties as trustees under an oral trust or oral agreement to hold and manage assets for Chantal and for breach of a loan agreement of Swiss Francs (“CHF”) 9.5 million with 3% p.a. interest (“the Loan Agreement”). Renslade (HK) is sued for dishonestly assisting BCS and Weber in their breach of fiduciary duties. The Defendants are also sued for conspiring and acting together with the intention of injuring Chantal and/or the Estate.
The background
- [5]
[5] The following background facts are not really in dispute. Insofar as they are, they constitute our findings of fact. Chantal co-invented a compound called Ethocyn in 1980. Her co-inventor, one Walter J. Kasha (“Walter”), does not feature in the evidence but nothing turns on that. The Ethocyn compound had to be manufactured or synthesized in a laboratory. It was a skin product that was said to make the skin look younger and better toned. There was a finished product sold over the counter or through other channels like television and telemarketing. The Ethocyn compound was also sold to cosmetic manufacturers who would incorporate this compound into their products.
- [6]
[6] Chantal was a gifted individual. As a chemist and scientist, she co-invented the Ethocyn compound and co-authored a number of articles in relation to compounds and products in relation to her areas of interest and work. She was also a Member of the California State Bar from 1981 with a juris doctor degree (1981, the University of West Los Angeles) and was admitted to practice in the Supreme Court of California and the Central District Court. She was a partner in a law firm, Allison Williamson & Burnison (1981-1983) and General Corporate Counsel to a public pesticide company.
- [7]
[7] Sometime prior to 21 May 1982, Chantal and Walter assigned their rights to the inventions and patents of Ethocyn (“the Ethocyn Rights”) to CBD Inc, a Californian company, which in turn licensed the Ethocyn Rights to CBD Pharmaceutical Corporation (which was incorporated in 1979 as Innovations International Inc and changed its name to Chantal Pharmaceutical Corporation in 1982). On 21 May 1982, CBD Pharmaceutical Corporation licensed those rights to Chantal Pharmaceutical Corporation (“Chantal Pharmaceutical”). In March 1994, Chantal Pharmaceutical licensed the Ethocyn Rights to Chantal Skin Care Corporation (“CSC”). Chantal Pharmaceutical and CSC will be collectively referred to as “the Chantal Companies” in this judgment. All the aforementioned companies are Californian corporations. For the purposes of this judgment, we find, and it is not really in dispute, that Chantal was resident in California, more particularly, in or in the vicinity of Los Angeles. However, her business encompassed at least the USA, Asia and Europe.
- [8]
[8] On 6 May 1996, a class action was commenced against Chantal Pharmaceutical and Chantal by purchasers of the common stock of Chantal Pharmaceutical for allegedly issuing false statements on the financial performance of Chantal Pharmaceutical by overstating its revenues, which operated to artificially inflate the price of Chantal’s common stock. It was alleged that Chantal sold at least 300,000 of her stock for at least US$6.3 million. It is alleged that, because of these false statements, the stock rose from “$6-9/16 on July 10, 1995 to $28-1/8 on December 29, 1995” but when certain reports concerning its financial condition surfaced, the stock fell from “$19-1/8 per share to $7-5/16 per share on January 8, 1996 on a huge volume of 7.7 million shares”. The class action was brought pursuant to the Securities Exchange Act of 1934 (15 U.S.C. §§78j(b) and 78t(a)) and rules promulgated by the Securities and Exchange Commission (17 C.F.R. §240.10b-5).
- [10]
[10] A Creditors’ Committee was appointed by the United States Trustee for the Chantal Companies. The Creditors’ Committee retained the Kriegsman Group and an investment banker and the latter also engaged the services of one Stan Teeple (“Teeple”), a work-out consultant, in locating a potential buyer for the debtors’ rights and assets. It is not in dispute that a prospectus was prepared and sent out to about 20 prospective buyers. A draft of this prospectus was sent to Chantal and her lawyer on 19 June 1999 which was said to be prepared by one Jerry Seelig (a Managing Director with the Kriegsman Group ) based on an earlier version by Teeple. There is evidence, marked “Draft”, of a reply from Mr Esterkin, Chantal’s lawyer, noting, inter alia, that Chantal had no control over the selection of the Kriegsman Group or its activities or its gathering of information for the brochure and that she has no control over the parties to whom the brochure would be sent. That letter also corrected inaccuracies and distanced Chantal from the projections made in the brochure. There may have been subsequent discussions between the parties on the terms and conditions and the sale of the Chantal Companies’ assets before the prospectus was sent out to prospective buyers identified and chosen by the Kriegsman Group and/or Teeple as parties likely to have an interest to purchase the Ethocyn Rights and assets from the Chantal Companies.
- [12]
[12] The material terms of the APA were as follows:
(a) CBD Pharmaceutical transferred its patent rights (which expired in 2004) to the Chantal Companies; this was effected through a Patent and Licence Transfer Agreement with the Chantal Companies on 20 October 1999;
(c) the transfer of the patent rights and licences to Renslade (NZ) was free and clear of all liens, encumbrances and claims;
(d) certain releases were given by the Chantal Companies for possible claims against CBD Pharmaceuticals, their agents, employees, attorneys, successors and assigns including Chantal; and
(e) as a condition of the sale, Chantal entered into a consultancy agreement with Renslade (NZ) to serve as Chairman and Chief Executive Officer on agreed terms which included a payment of US$100,000 a year for business transition services and US$50,000 a year for similar services to Renslade (NZ)’s US subsidiary, E Cosmetics (“the Consultancy Agreement”).
- [13]
[13] On 23 May 2000, Renslade Singapore Pte Ltd (subsequently re-named Renslade Holdings Pte Ltd (“Renslade (S)”)) was incorporated. The Ethocyn Rights were subsequently transferred from Renslade (NZ) to Renslade (S). When exactly this occurred is not clear. Baker deposes that it was probably sometime in 2002, between BCS’s name change on 26 July 2002 and Chantal’s email to Weber of 20 September 2002 when she expressed her preference for BCS to be the distributor of Nu Skin products. There is an assignment of the Ethocyn Rights dated 24 May 2000 from Renslade (NZ) to Renslade (S), where Weber signed on behalf of Renslade (S). Evidence emerged that this decision was probably made in September 2001 but it was decided to backdate this assignment to 24 May 2000.
- [14]
[14] On or around 22 May 2001, the Class Action Suit against Chantal and the Chantal Companies was brought to an end with the filing of a Stipulation of Settlement.
- [15]
[15] On 1 April 2002, the Ethocyn Rights were transferred from Renslade (S) to BCS.
- [16]
[16] In 2002, Renslade (S) bought out the Chantal Companies’ rights to the Ethocyn Royalty (“the Royalty Buyout”) for US$135,000. This Royalty Buyout, which was supported by the Creditors’ Committee, was sanctioned by the US Bankruptcy Court on 23 July 2002.
- [17]
[17] As noted above, Renslade (HK) was incorporated in Hong Kong on 5 November 2007. In or around 2007, money was transferred from BCS to Renslade (HK). There were probably other sums so transferred as Renslade (HK) was used as a repository of the profits earned from the sale of Ethocyn products.
- [18]
[18] While the facts set out in [13]–[17] are not really in dispute, the surrounding circumstances, the reasons behind those facts, and the conclusions to be drawn from them are disputed.
- [19]
[19] Baker, as executor of the Estate, alleges that Chantal provided the monies for the purchase of the Ethocyn Rights and the Royalty Buyout and set up Renslade (NZ) to hold these assets. All monies earned over the years from these Ethocyn Rights belonged to Chantal. These were eventually transferred to Renslade (S), a company incorporated in Singapore by Weber. Weber alleges that he was offered and he purchased the Ethocyn Rights from Renslade (NZ) as a personal investment opportunity and the Ethocyn Rights and all monies earned from them belong to him and his companies.
- [20]
[20] This is therefore an appropriate juncture to set out the parties’ pleaded cases.
The parties’ pleaded cases
The plaintiff’s case
- [21]
[21] When the Chantal Companies filed for bankruptcy, Chantal wanted to purchase the Ethocyn Rights but she faced opposition. Chantal therefore instructed a lawyer, Shane Weir (“Weir”), to choose and use a company to purchase those rights. Weir chose Renslade (NZ). Renslade (NZ) negotiated with the Chantal Companies and the Creditors’ Committee and reached an agreement as set out in the APA, the essential terms of which are set out above (at [12]). There were no other entities willing to purchase those rights despite the efforts of the Creditors’ Committee, their merchant bankers, the Kriegsman Group and the experienced work-out specialist, Teeple. The Bankruptcy Court approved the APA on 19 October 1999. On 20 October 1999, CBD Inc and CBD Pharmaceutical entered into the Patent and Licence Transfer Agreement with the Chantal Companies to transfer the Ethocyn Rights to the Chantal Companies, and the Ethocyn Rights were duly transferred to the Chantal Companies. On or around 20 October 1999, Renslade (NZ) acquired the Ethocyn Rights for US$325,000 from the Chantal Companies and this sum was provided by Chantal. Renslade (NZ) held the Ethocyn Rights on trust for Chantal and Weir was responsible for managing the trust.
- [22]
[22] In or around November 1999, Chantal entered into an agreement with Weber, pursuant to which Weber would acquire the Ethocyn Rights from Renslade (NZ) and hold any income or proceeds generated from the Ethocyn Rights on trust for Chantal (“the Trust”, and we shall use the term “the Trust Agreement” as set out in the parties’ Agreed Issues, see [63] below) (the “Oral Agreement”) on the following terms:
(a) Renslade (NZ) would transfer the Ethocyn Rights to a company incorporated in Singapore (“the Acquiring Company”) and owned or controlled by Weber;
(b) the Acquiring Company would not have to provide any monetary consideration for its receipt of the Ethocyn Rights;
(c) the Acquiring Company and any company that acquired the Ethocyn Rights or any income or proceeds generated therein, would hold it on trust for Chantal, save for 5% of the said income or proceeds which would be paid to Weber (“the Trust Assets”);
(d) the Trust Assets would be ultimately held by a Singapore entity which will be a trustee; and
(e) Weber would be responsible for managing and overseeing the Trust.
- [23]
[23] By way of an assignment dated 24 May 2000, Chantal transferred the Ethocyn Rights from Renslade (NZ) to Renslade (S), a company incorporated in Singapore on or about 23 May 2000. Weber was the sole shareholder of Renslade (S). By way of a Deed dated 1 April 2002, Weber transferred the Ethocyn Rights from Renslade (S) to BCS (“the Deed of Assignment”). BCS became the trustee of the express trust over the Ethocyn Rights and any income or proceeds generated from them and of which Chantal was the sole beneficiary. On August 2002, Renslade (NZ) or Renslade (S) paid US$135,000 to the Chantal Companies to buy out the Chantal Companies’ rights to the Ethocyn Royalty. This sum was provided by Chantal.
- [24]
[24] In the alternative, on the above facts, a resulting trust was created over the Ethocyn Rights in favour of Chantal as the sole beneficiary. Chantal provided the sum of around US$325,000 for Renslade (NZ) to acquire the Ethocyn Rights from the Chantal Companies and a sum of US$135,000 for Renslade (NZ) or Renslade (S) to buy out the Chantal Companies’ rights to the royalties of the Ethocyn Rights. When Renslade (NZ) transferred the Ethocyn Rights to Renslade (S), Renslade (S) did not give any monetary consideration for the transfer. Chantal did not intend to give the Ethocyn Rights to Renslade (NZ) or Renslade (S) or to any other company to which the Ethocyn Rights were transferred. Instead, Chantal and Weber agreed to make Renslade (S) or any other company which held the Ethocyn Rights the legal owner so as to keep Chantal’s interest in the Ethocyn Rights confidential.
- [25]
[25] On 26 June 2003, BCS entered into a supply and distribution agreement (“the Nu Skin SDA”) with Nu Skin International Inc (“Nu Skin”). Chantal negotiated and executed the Nu Skin SDA on behalf of BCS. Under the Nu Skin SDA, BCS agreed to supply Ethocyn to Nu Skin for its usage and distribution. In return, Nu Skin would make direct payments to BCS. From around 2007 to 2017, Nu Skin made payments under the Nu Skin SDA to BCS. 95% of the monies paid by Nu Skin to BCS were held on trust for Chantal (“the Trust Monies”), while the remaining 5% were retained by BCS or Weber as commission. In or around 2016, the Defendants started retaining 10% of the monies paid by Nu Skin to BCS without Chantal’s knowledge and/or consent.
- [26]
[26] In or around 2007, Weber informed Chantal that the Trust Monies would be transferred from BCS to Renslade (HK). Renslade (HK) acted as BCS’s and Weber’s agent in relation to the Trust Monies.
- [27]
[27] From time to time, upon Chantal’s request, Weber would transfer the Trust Monies from BCS and/or Renslade (HK) to Chantal, entities controlled by her and/or entities involved in the production and/or marketing of the Ethocyn products or protection of the Ethocyn Rights. To date, BCS and/or Renslade (HK) are still in possession and/or control of all or some of the Trust Monies and BCS is still in possession of the Trust Assets.
- [28]
[28] In or around June 2014, Weber asked and Chantal agreed to lend Weber CHF6 million from the Trust for Weber’s investment in a ski resort. Weber agreed to pay 3% interest p.a. on the borrowed sum. In 2015, Chantal discovered that Weber had in fact taken CHF9.5 million from the Trust instead.
- [29]
[29] In September 2015, Chantal was diagnosed with colon cancer. From May 2016 until her death in October 2016, Chantal repeatedly sought an account of the Trust Assets and the Trust Monies from the Defendants. After Chantal’s passing in October 2016, Baker on behalf of the Estate repeatedly sought an account and return of the Trust Assets and Trust Monies from the Defendants but to no avail.
- [30]
[30] Heika also attempted to seek an account of the Trust Assets from the Defendants.
(a) In July 2016, Heika attended a meeting in Zurich with Weber and Urs Wehinger (“Wehinger”), a Swiss attorney (“the July 2016 Meeting”).
(b) At the July 2016 Meeting, BCS and/or Weber provided a summary of the Trust Monies owing to Chantal’s Estate. The said summary showed that at least US$41,823,541.14 is owing to Chantal. Heika discreetly took a photograph of the said summary. Heika was also shown a note recording the loan of CHF9.5 million; the bond was signed by Weber and stated that CHF9.5 million was payable with interest of 3% in or around June 2017.
(c) At a meeting on 12 December 2016 (“the December 2016 Meting”), attended by Heika, Wayne Johnson (“Johnson”, the attorney for Chantal’s Estate), Weber, Wehinger, and Ralf Wojtek (“Wojtek”, an attorney acting for BCS), the various means by which the Trust Monies and Trust Assets would be returned and/or transferred to Chantal’s Estate were discussed. During the December 2016 Meeting, Weber and Wehinger also represented to Heika and Johnson that Weber had established a foundation and contributed the Trust Assets to the foundation, with Heika and Birka as the beneficiaries. However, no such foundation had been established.
- [31]
[31] By way of two letters dated 3 May 2017 and 12 May 2017 from Baker to Johnson, and Johnson to Wojtek, Baker sought an account of the Trust Monies and Trust Assets by 15 May 2017. The Defendants failed to do so.
- [32]
[32] Baker, on behalf of the Estate, makes the following claims against the Defendants:
(a) BCS breached its fiduciary duty to Chantal or Baker as trustee of the Trust by failing to provide an account of the Trust and the Trust Monies; and failing to return the Trust Assets and Trust Monies to the Estate;
(b) Weber breached his fiduciary duty to Chantal and/or Baker as manager of the Trust by failing to provide an account of the Trust and Trust Monies to Chantal and Baker; failing to procure BCS and/or Renslade (HK) to return the Trust Assets and the Trust Monies to the Estate; and failing to return the CHF9.5 million which Weber took from the Trust in or around 2014 along with 3% interest;
(c) Weber breached the Loan Agreement by failing to return the CHF9.5 million with 3% interest;
(d) Renslade (HK) dishonestly assisted BCS and Weber in their breaches of fiduciary duty; and
(e) the Defendants conspired and/or acted together with the intention of injuring Chantal and/or Baker.
- [33]
[33] Baker, on behalf of the Estate, claims and/or seeks the following remedies:
(a) a declaration that BCS and/or Renslade (HK) hold the Trust Assets and/or Trust Monies on trust for the Estate of Chantal;
(e) judgment against Weber for CHF9.5 million together with 3% interest; and
(f) interest and costs.
The Defendants’ defences
- [34]
[34] BCS and Weber deny there was any kind of agreement between Chantal and Weber for Weber to acquire and hold the Ethocyn Rights and any income or proceeds generated on trust for Chantal.
- [35]
[35] The Defendants aver that Chantal wished to locate a purchaser for the Ethocyn Rights and assets held by Renslade (NZ) and Chantal was introduced to Weber by a mutual friend. Weber saw the sale of the Ethocyn Rights as a good business opportunity and agreed to purchase the same from Renslade (NZ) for his own benefit. Renslade (S), a company controlled by Weber, acquired the assets from Renslade (NZ) for US$325,000 which was paid for by BCS with monies belonging to BCS and/or Weber and this sum was not provided for by Chantal.
- [36]
[36] BCS and Weber acquired the Ethocyn Rights using Renslade (S) because:
(a) in 2000, Weber was carrying on business in Singapore through BCS and he wanted to administer all his businesses from Singapore; and
(b) Weber did not want to transfer the Ethocyn Rights to BCS as BCS already had other business streams and Weber did not want to conflate those with the new business concerning the Ethocyn Rights.
- [37]
[37] Nu Skin did not want to contract with Renslade (S) since Renslade (S) was a shell company. Hence, the Ethocyn Rights were transferred to BCS for BCS to deal with Nu Skin.
- [38]
[38] From 25 May 2000, until her death, Chantal worked for Renslade (S) as a consultant and assisted Renslade (S) and BCS with the exploitation of the Ethocyn Rights.
- [39]
[39] Pursuant to the Nu Skin SDA, Nu Skin would pay BCS for products made with Ethocyn.
- [41]
[41] Renslade (HK) claims that it has no knowledge or involvement in the alleged Trust never held any monies on trust for Chantal; and did not act as the agent of BCS and Weber in relation to the alleged Trust or Trust Monies.
- [43]
[43] On the facts pleaded by the Estate, the alleged Trust was governed by California law and no valid trust could have been created under California law:
(a) there was no intention to create a trust and the alleged Trust was made orally with no documentation confirming or evidencing Chantal’s intention to create a trust; and
(b) there is no documentary evidence as to the designation of identity of any beneficiary of the alleged Trust.
- [44]
[44] The alleged Trust or alleged Oral Agreement would be for an illegal purpose:
(a) the Ethocyn Rights were purchased by Renslade (NZ) pursuant to the US Bankruptcy proceedings in which, inter alia, Chantal’s orchestration of the purchase of the Ethocyn Rights was not disclosed;
(b) Chantal stated in her declaration, in support of the sale of the Ethocyn Rights to Renslade (NZ), under penalty of perjury, that she “did not ask Renslade (NZ) to require that the patents be transferred as part of the [Chantal Companies’] sale of their rights and assets”;
(d) on the basis of Chantal’s declaration, the US Bankruptcy Court found that:
(i) Renslade (NZ) had an arm’s length relationship with the Chantal Companies and that all terms were fully disclosed; and
(ii) neither Renslade (NZ) nor the Chantal Companies engaged in conduct that would cause the sale of the Ethocyn Rights to be avoided under US Bankruptcy Law.
- [45]
[45] Chantal’s arrangement for Renslade (NZ) to purchase the Ethocyn Rights is illegal under ss 152 and 157 of Title 18 of the United States Code.
- [46]
[46] Furthermore, no valid trust can be created where the settlor and the beneficiary are one and the same person. Even if there is a valid Trust, the Trust must be accompanied by the issuance of a separate Taxpayer Identification Number under US estate tax law, failing which, the Trust Assets cannot be claimed by the estate of the settlor.
- [47]
[47] In addition, the alleged Oral Agreement and/or alleged Trust would be illegal, void or unenforceable as being contrary to the public policy of Singapore. On the Estate’s case, Chantal and Weber would be carrying out a fraudulent transaction under US Bankruptcy Law and/or fraud on the creditors of the Chantal Companies in the US Bankruptcy Court proceedings.
- [48]
[48] On 6 May 1996, a class action suit was commenced by purchasers of common stock of Chantal Pharmaceutical against Chantal and Chantal Pharmaceutical for securities fraud. When the Ethocyn Rights were being sold to Renslade (NZ), the class action suit was still ongoing.
- [49]
[49] On 21 May 2001, counsel for the class action suit proposed a settlement of the same. Counsel had concluded that Chantal and Chantal Pharmaceutical would be unable to satisfy any money judgment as Chantal had no significant assets and Chantal Pharmaceutical was undergoing insolvency proceedings. As part of the settlement agreement, Chantal had stated that her net worth was less than US$350,000 and agreed to deliver detailed financial information to prove the same. The settlement was approved by the court on 31 July 2001.
- [50]
[50] Weber denied there was any loan to him. As the controlling shareholder of Renslade (HK), Weber invested CHF9.5 million from the profits generated by the Nu Skin business in bonds.
- [51]
[51] After Chantal was diagnosed with cancer, Chantal asked Weber to ensure that her daughters would be financially supported until they reached the age of 28 in the event of her passing and Weber agreed. Weber intended to create a fund of monies to be released to the two daughters, and was going to put some of the profits generated from the Ethocyn Rights into the fund. This was not done as Weber was sued by the Estate.
- [52]
[52] Heika attended the meeting in Zurich in or around July 2016 on behalf of Chantal as she was too ill to travel. At the meeting, Weber showed Heika a draft account of the estimated sums for the income generated by the Ethocyn Rights to assure her and Chantal that there were monies available for the creation of the fund.
- [53]
[53] At the December 2016 Meeting, Heika said she wanted to acquire the majority shareholding of the company to be established to hold the Ethocyn Rights and the Nu Skin SDA from BCS. No agreement was eventually reached as no reasonable purchase offer was presented and BCS and Weber wanted to maintain ownership and control over the Ethocyn Rights and profits generated therefrom.
- [54]
[54] The Defendants therefore deny they owed any fiduciary duty towards Chantal or the Estate. The Defendants deny all claims and reliefs sought by the Estate in their claim.
The Plaintiff’s reply
- [55]
[55] Baker avers that Singapore law is the governing law of the agreement and the Trust. He denies that no valid trust could have been created on the facts pleaded by the Estate.
(a) Sections 15201 and 15202 of the Probate Code do not require written documentation of a settlor’s intention to create a trust and written documentation of the beneficiary’s identity and there is clear and convincing evidence of the existence of the Trust.
(b) Baker denies that the agreement and the Trust would be for an illegal purpose.
(c) Chantal’s arrangement of using Renslade (NZ) to purchase the Ethocyn Rights in the US Bankruptcy proceedings was not contrary to Chantal’s declaration and/or ss 152 and 157 of Title 18 of the United States Code and/or illegal.
- [56]
[56] Baker also submits that a self-settled trust is not invalid under California law. In addition, the Trust is not an irrevocable trust, so the US Estate tax law requirements highlighted by the Defendants do not apply.
- [57]
[57] Even if the Trust and/or Agreement were invalid under California law:
(a) BCS, as the trustee, would hold the legal title to the Trust Assets or Trust Monies on a resulting trust for Chantal who is the settlor of the Trust; and
The Issues
- [58]
[58] The parties have put forward an Agreed List of Issues. There was also a list of issues by the Estate that were not agreed to by the Defendants and a list of issues put forward by the Defendants that were not agreed to by the Estate.
- [59]
[59] The Agreed List of Issues are as follows.
(a) Was there a Trust Agreement between Chantal and Weber as pleaded by the Estate in paras 13 and 14 of the Statement of Claim (Amendment No. 3)?
(b) When was such Trust Agreement formed, between whom and what were the terms thereof?
(c) Did Renslade (NZ) hold the Ethocyn Rights on trust for Chantal?
(d) Who provided the funds, if any, for Renslade (S) to acquire the Ethocyn Rights from Renslade (NZ)?
(e) Did Renslade (NZ) or subsequently Renslade (S) acquire legal and beneficial ownership to the Ethocyn Rights and assets?
(f) If a Trust Agreement existed between Chantal and Weber, what is the governing law of any alleged Trust (as defined at para 13C of the Defence (Amendment No. 4) (“Defence (Amd 4)”) dated 8 July 2019)?
(g) If the Alleged Trust was invalid, are the Defendants nevertheless holding the Trust Assets and/or Trust Monies (as defined at paras 14(c) and 24 of the Statement of Claim (Amendment No. 3) (“Statement of Claim (Amd 3)”) dated 5 July 2019) and/or any other income of proceeds generated from the Trust Assets on a resulting trust and/or constructive trust for Chantal’s Estate under California Law?
(h) If the Alleged Trust was valid under California law, can the assets alleged to be held on trust be claimed by Chantal’s Estate?
(i) Are the Trust Agreement and/or Alleged Trust illegal, void, or unenforceable as being contrary to the public policy of Singapore?
(j) If the Alleged Trust is illegal, void, or unenforceable as being contrary to the public policy of Singapore, are the Defendants nevertheless holding the Trust Assets and/or Trust Monies and/or any other income or proceeds generated from the Trust Assets on a resulting trust for Chantal’s Estate under Singapore law?
(k) What was the reason for the 5% and/or 10% proceeds retained by BCS from the sale of the Ethocyn products pursuant to the Nu Skin SDA?
(l) What was the purpose of the transfer of monies from BCS and/or Renslade (HK) to:
(i) Chantal;
(ii) entities controlled by Chantal; and/or
(iii) entities involved in the production or marketing of Ethocyn products or the protection of the Ethocyn Rights?
(m) If the Alleged Trust and/or Trust Agreement existed between Chantal and Weber, was BCS’s and/or Weber’s retention of 10% of the monies paid by Nu Skin to BCS from in and around 2016 without Chantal's knowledge and/or consent a breach of the Trust Agreement?
(n) If the Alleged Trust and/or Trust Agreement existed between Chantal and Weber, was the CHF9.5 million which the Defendants withdrew from the profits made under the Nu Skin SDA an unauthorised withdrawal from the Trust Monies?
(o) If a Trust Agreement existed between Chantal and Weber, did Chantal, Baker and/or Heika and Birka seek an account of the Trust from the Defendants?
(p) What took place at the meetings between, inter alia, Heika and Weber in or around July 2016 and on or around 12 December 2016?
(q) Was there an agreement entered into at the meeting on or around 12 December 2016 for the Defendants to transfer Trust Assets and/or Trust Monies and/or any other income or proceeds generated from the Trust Assets to Chantal’s Estate?
- [60]
[60] The Estate put forward a list of additional issues that were not agreed to by the Defendants.
(a) Did Chantal provide the funds for Renslade (NZ) to acquire the Ethocyn Rights from the Chantal Companies?
(b) Who provided the funds for Renslade (NZ) or Renslade (S) to buy out Chantal Companies’ rights to the Ethocyn Royalty?
(c) Were the Ethocyn Rights and assets transferred from Renslade (NZ) to Renslade (S) because Weber saw the sale of the Ethocyn Rights and assets as a good business opportunity and agreed to purchase them for his own benefit?
(d) Were the Ethocyn Rights and assets transferred from Renslade (S) to BCS because Nu Skin did not want to enter into a contract with Renslade (S)?
(e) If the Trust and/or Trust Agreement pleaded by Chantal’s Estate is governed by California law, was the Trust and/or Trust Agreement invalid under California law?
(f) What was the purpose of the transfer of proceeds generated under the Nu Skin SDA to Renslade (HK)?
(g) What was Chantal’s role in relation to BCS’s business and transactions with Nu Skin under the Nu Skin SDA?
(h) Was there an agreement, as alleged by the Defendants, between Chantal and Weber for Weber to ensure that Chantal’s daughters were financially supported until they reached the age of 28 in the event of Chantal’s passing and for Weber to create a fund of monies, using some of the profits generated from the Ethocyn Rights, to be released to Chantal’s daughters?
- [61]
[61] The Defendants also put forward a list of additional issues that were not agreed to by the Estate.
(a) Did Chantal provide the funds for Renslade (NZ) to acquire the Ethocyn Rights from the Chantal Companies and, if so, were these out of her own funds?
(b) Did Chantal provide the funds for Renslade (NZ) or Renslade (S) or BCS to buy out Chantal Companies’ rights to the Ethocyn Royalty and, if so, were these out of her own funds?
(c) If the Alleged Trust (as defined at para 13C of the Defence (Amd 4)) pleaded by the Estate is governed by California law, was the Alleged Trust valid, legal and enforceable under California law?
(d) Did Chantal claim and receive operating and production costs from BCS and/or Renslade (HK) on behalf of E. Cosmetics Corporation and/or BCS Pharma for manufacturing Ethocyn products, which were higher than the actual costs incurred, leading to a profit taken of more than US$18 million by Chantal?
- [62]
[62] Many of the above “issues” in [60] and [61] are more in the nature of findings of fact. Some of them, like that set out in [61(d)], do not arise from the pleadings and the Defendants have not filed a counterclaim for the US$18 million allegedly over-paid to Chantal. The answers to the relevant questions will be found, expressly or impliedly, in our findings of fact in this judgment.
- [63]
[63] At the heart of this dispute are two underlying issues:
(a) Was there a Trust Agreement between Chantal and Weber and his companies (BCS and Renslade (HK)) to hold the Ethocyn Rights and all income and proceeds therefrom on trust for Chantal (“Trust Agreement”) or did Weber purchase the Ethocyn Rights for his own investment in his own right?
(b) If there was a valid Trust Agreement, was it unenforceable or void as a result of an illegality under Singapore law and/or California law?
There is a discrete issue, depending upon our findings, as to the existence of the Trust Agreement, relating to the alleged loan and recovery of CHF9.5 million with 3% interest.
The Defendants’ election not to call evidence and a submission of no case to answer
- [65]
[65] The Estate called Baker, Heika and the Estate’s lawyer Johnson as witnesses. After they gave their evidence, the Defendants elected not to call any evidence and submitted that there was no case to answer. As a result of this election, the affidavits of evidence-in-chief (“AEICs”) of Weber and Wojtek, a lawyer representing Weber, were not admitted into evidence.
The burden of proof when electing not to give evidence and submission of no case to answer
- [66]
[66] The Defendants have the right to submit that there is no case to answer, following the exercise of their right to elect not to call evidence: O 35 r 4(3) and O 110 r 3(1) of the Rules of Court (Cap 322, R 5, 2014 Rev Ed). Not surprisingly, counsel for the plaintiff and the defendants, Mr Cavinder Bull SC and Mr Alvin Yeo SC respectively, gave different emphases to the tests that should be applied when a defendant elects not to call evidence and submits that there is no case to answer.
- [67]
[67] The Court of Appeal in Lena Leowardi v Yeap Cheen Soo [2015] 1 SLR 581 (“Lena Leowardi”) ruled that where there is a submission of no case to answer, the test is whether the plaintiff’s evidence at face value establishes no case in law or whether the evidence led by the plaintiff is so unsatisfactory or unreliable that its burden of proof has not been discharged (at [23]). The threshold against which the claims are to be assessed is that of whether the plaintiff has established a prima facie case against the defendant, and the plaintiff need not prove his case on a balance of probabilities (Lena Leowardi at [24], citing Tan Juay Pah v Kimly Construction Pte Ltd and others [2012] 2 SLR 549 at [37]).
- [68]
[68] In assessing whether the plaintiff has established a prima facie case, the court will assume that any evidence led by the Appellant was true unless it was inherently incredible or outside of common sense. Where circumstantial evidence is relied on, it need not give rise to an irresistible inference as long as the desired inference is one of the possible inferences (Lena Leowardi at [24], citing Relfo Ltd (in liquidation) v Bhimji Velji Jadva Varsani [2008] 4 SLR(R) 657 (“Relfo”) at [20]).
- [69]
[69] These tests have been authoritatively set out in Lena Leowardi and we do not understand how Mr Bull SC or Mr Yeo SC can submit otherwise. However, when those principles are applied to the facts before us, there are nuances and allied principles which come into play:
(a) Mr Yeo SC is quite correct to say that he can test the Estate’s evidence to see if they do indeed establish a prima facie case. For example, Mr Yeo SC submits that the Estate has no evidence – besides an allegation by Baker – to show that the Ethocyn Rights were assigned from Renslade (NZ) to Renslade (S) for no consideration, and Baker was not even privy to or possessed with personal knowledge of the events then. In a sense, the Estate has to prove a negative. Instead, Mr Yeo SC submits that the available evidence – a Deed of Assignment – although backdated, does recite that it was assigned for value (see Lena Leowardi at [25], citing Lim Eng Hock Peter v Lin Jian Wei [2009] 2 SLR(R) 1004 at [210]). Whether that takes the Defendants beyond the gates will be examined below.
(b) Mr Yeo SC is also entitled to submit that even if the Estate has established a prima facie case, the trust was illegal or not enforceable as being tainted with illegality.
(c) Mr Bull SC on the other hand can legitimately submit that if circumstantial evidence is relied upon, it does not have to give rise to an irresistible inference as long as the desired inference is one the possible inferences (see Lena Leowardi at [24], citing Relfo at [20]); and so long as that evidence and inference is not inherently incredible or outside of common sense, the court will assume it is true.
(d) Mr Bull SC is also entitled to emphasize that, if the Estate makes out a prima facie case and the Defendants choose not to call evidence and submit that there is no case to answer, then, bearing in mind the above principles, the failure to offer evidence could be fatal to the defendants’ case (see Thio Keng Poon v Thio Syn Pyn and others and another appeal [2010] 3 SLR 143 at [42]).
(e) It is correct that no adverse inference ought to be drawn by a defendant’s making of a submission of no case to answer. However, if a court were to look at a particular email or letter authored by the defendant and its contents can be fairly said to point to the existence of certain facts that satisfy the prima facie test, but the court does not have the benefit of an explanation from the defendant that that was not what the defendant meant, the plaintiff’s construction of the particular email or letter would prevail.
(f) We also note that a number of Chantal’s emails, facsimiles and documents are cryptic. She is no longer around to explain them or to fill any gaps that exist. Baker may tell us what he thinks it means, either from what Chantal may have told him whilst she was alive or from what he knows or concludes by going through her many documents. What weight we give to his evidence must be carefully calibrated when applying the tests enumerated above.
(g) Similarly there are emails and facsimiles from one Christine Yong (“Christine”) and one Hartono, who were employees of the Defendants, to Chantal or other persons. The Estate’s construction of these emails and facsimiles will prevail as long as the construction or inferences are reasonable and not inherently incredible or outside of common sense. The defendants are in no position to attempt to put forward the context in which they should be read. The rules to be applied are those set out above at [67] and [68].
- [70]
[70] Having set out these principles to be applied on an election by the defendants not to call evidence and submit that there is no case to answer, we now turn to consider the evidence.
Evaluation of the evidence and findings of fact
- [71]
[71] It will be convenient to make our findings of fact and state our conclusions in stages.
The purchase of the Ethocyn Rights from the Chantal Companies
- [72]
[72] We find that Chantal wanted to purchase the Ethocyn Rights from the Chantal Companies in the Chapter 11 proceedings but she did not want anyone – including the creditors, the Creditors’ Committee, the Kriegsman Group, Teeple, their lawyers and the Bankruptcy Court – to know that she was behind the bid for the Ethocyn Rights. There was evidence, and we so find, that there were quite a large number of affected stockholders and creditors, some of whom had lost significant amounts of money. In a second application filed on 3 November 1999 by Chantal Companies’ counsel in the US Bankruptcy Court for an interim payment of their fees and disbursement, they state that they answered numerous telephone calls from the 1,500 creditors and over 1,750 stockholders and added that “[u]nfortunately, many people have lost significant amounts of money and it would be inappropriate to ignore their telephone calls…”. This application for interim payment was granted by the US Bankruptcy Court on 23 November 1999.
- [73]
[73] We have no direct evidence from Chantal for her motives for doing so. Baker and Heika gave evidence that Chantal had received death threats from disgruntled shareholders who had lost money in the failure of the Chantal Companies and they would have taken any purchase by Chantal of the Ethocyn Rights badly. There was some evidence, described as prima facie evidence by Mr Bull SC, that there were such death threats. In her AEIC, Heika, who was 12 years’ old at the time of the bankruptcy proceedings, remembered that her mother received death threats and became fearful for their safety. Heika deposes that her mother changed their residence to her grandfather’s house, diverted all her mail there and hired a bodyguard to protect her and Birka. Heika exhibited a picture of herself and a man, who she claimed to be her bodyguard. Heika was not challenged on this. Baker too was not directly challenged on this in cross-examination. All Baker was cross-examined on was that Chantal could not have been fearful of death threats so many years later (in 2010, 2011, 2013 or 2014) and that these death threats were a cover to explain the inconsistencies in the documents. We note that Baker only met Chantal in 2002. In his AEIC, Baker could only tell us what Chantal had told him at some later point in time after 2002. However, his credibility upon cross-examination on this issue remained intact and we accept it but caution ourselves as to its weight. There is also unchallenged documentary evidence that Chantal used her father’s address for correspondence and corporate documents and even her death certificate carries the address of her father’s house. We should point out two things. First, other than bare statements, albeit on oath, we have no evidence at all as to the nature of or form of these death threats, whether by telephone calls or anonymous notes or letters in the post. Secondly, we would have expected that with death threats of a serious nature, some reports would have been made to the police. There was however, no such evidence. Nevertheless, this court has to assume that the evidence led by the Estate is true unless it was inherently incredible or outside of common sense (Lena Leowardi at [24]). In this case, that Chantal received death threats from disgruntled shareholders or creditors who had lost significant amounts of money is one of the possible inferences of the circumstantial evidence and we accordingly accept that to be the case. Had Weber come to trial to challenge Baker’s evidence on this, for example, by testifying that Chantal had never told him of any death threats, we may well find otherwise. In any event, the issue of whether Chantal actually received death threats is not a pleaded issue and should not be of disproportionate significance.
- [74]
[74] We also think it more likely than not that Chantal believed in her own product or invention and needed to put her and her companies’ financial problems behind her so that she could exploit her invention to its full potential. If the Creditors’ Committee knew she was interested in buying the Ethocyn Rights, they were likely to have tried to extract a higher price; whether they could succeed or not is an entirely different matter and there is no direct evidence on this. There is nothing intrinsically wrong with or exceptional in a debtor wanting to purchase its own assets, but there certainly would have been heightened scrutiny of the sale and accompanying agreements if this had been made known. We think Chantal also had an interest in securing the Ethocyn Rights free and clear of all claims, liens and encumbrances as well as settling the Class Action suit against her. Chantal also wanted to move the Ethocyn Rights offshore to maintain opacity as to its ownership and to take advantage of more favourable tax regimes.
- [75]
[75] We find that the Estate has made out its case that Chantal was responsible for deciding upon a New Zealand corporation to purchase the Ethocyn Rights. There was ample evidence on this score. Pursuant to her decision, Chantal instructed Weir, a lawyer practising in Hong Kong, to use a company in New Zealand and this resulted in the acquisition of a shelf company, which was re-named Renslade (NZ). Chantal’s business activities had hitherto, and we say unsurprisingly, not been confined to the USA. It is stated in the draft prospectus prepared to attract bids, which we accept, that in 1995 the Chantal Companies entered into additional distribution agreements with a Hong Kong company for the Pacific Rim; “Hong Kong” was later corrected by Chantal’s lawyer to Taiwan. The distributor was one Roger Chang who is mentioned in the US Bankruptcy Court filings (although it also appears that there was a former Chantal product distributor in Hong Kong called Lisa Lai). Under Article XII of the APA, notices to be sent to the purchaser Renslade (NZ) were to be sent to: “c/o Weir & Associates, 5th Floor, Landmark East, 12 Ice House Street, Central, Hong Kong”. The notice provision in the Consultancy Agreement between E. Cosmetics (a Nevada corporation) and Chantal dated 19 October 1999 provided for service on E. Cosmetics at 5757 West Century Boulevard, Los Angeles (the address of the Chantal Companies) with a copy to “Shane Weir” at his Hong Kong office address. There is a facsimile dated 25 June 1999 from Weir to Ken Whitney of New Zealand law firm Ross & Whitney to acquire a shelf company in New Zealand. Weir wrote:
- [76]
[76] There are sufficient emails, facsimiles and documents to back up Baker’s account in his AEIC, viz, that Renslade (NZ)’s first directors were two partners of Ross & Whitney, Kenneth Whitney and Ian Ross; they were replaced on 15 October 1999 by one Ms Ka Wai Chan, who Baker believes to be Weir’s nominee. That would in all probability be the “Carrie Chan” referred to in Weir’s facsimile (at [75] above), as we also see a reference to “KW Chan in Hong Kong” in an email from Giles Kennedy to Noel Conway dated 21 November 1999 reporting the receipt of documents from her in relation to the issue of shares in Renslade (NZ) for filing in New Zealand as well as a Change of Directors Form filed for Renslade (NZ). We also find that Chantal was considering a holding company, Granville Limited (“Granville”), which was also controlled by Weir on behalf of Chantal. Legendary was another associated company and the facsimile referred to at [75] above states that it is also held by Granville. With these private companies and shareholdings, control could easily be structured or re-structured to maintain opacity in beneficial ownership.
- [77]
[77] We also find that Chantal considered using other nominal owners, called “figure heads” by her, to conceal the beneficial ownership of Renslade (NZ). This included one Dr Lalaine de la Cruz (“Lalaine”) who was a friend of her father’s working in the Philippines. The companies may also have been structured to accommodate investors in the business going forward. We see Wehinger, although a friend of Chantal, representing a group of investors called “SIG” who were settled out and mentioned in the US Bankruptcy Court papers. We find that Chantal suddenly lost her trust in Weir in November 1999 and changed her lawyer to a US attorney, Noel Conway. There was also a change of New Zealand lawyers to Colin Beyer and Giles Kennedy of Simpson Grierson Law, a law firm in Auckland (“Simpson Grierson”).
- [78]
[78] Whilst Baker might not know all the details, the documentary evidence, including emails and facsimiles, does show, quite convincingly, that it was Chantal putting all these arrangements in place. We see her ability to change lawyers and the lawyers taking instructions from her.
Chantal provided the funds to purchase the Ethocyn Rights and assets from the Chantal Companies
- [79]
[79] We find that Chantal provided the funds through her family company, SBC Pharmaceutical, to Renslade (NZ) to purchase the Ethocyn Rights and assets from the Chantal Companies in the Chapter 11 proceedings. The Defendants did not produce any documentary evidence or otherwise to contradict this, having elected not to call evidence. Mr Yeo SC tried valiantly to challenge the conclusions to be drawn from some of the documentary evidence. He did not succeed, not, we must say, for want of trying. We do accept that the emails, facsimiles and documents provided by the Estate do have some gaps and do not contain complete explanations. However, they are sufficient, at the very least on a prima facie basis, to piece together how Chantal set about getting a New Zealand corporation to make a bid for the Ethocyn Rights and assets of the Chantal Companies.
- [80]
[80] We accept the evidence given by the Estate that CBD Pharmaceutical Corporation, a company owned by Chantal’s family, transferred US$800,000 to P F Wong & Co, Solicitors in Hong Kong (“P F Wong”), as evidenced in a Hang Seng Bank Credit Advice dated 7 January 1999, and Chantal records this as a fact in her own handwriting.
- [81]
[81] There is a handwritten note in the Agreed Bundle dated 1 March 2000, entitled “CHRONOLOGY” (“the Handwritten Chronology”). We find the handwriting has been convincingly identified – by both Heika and Baker – as that of Chantal’s. At the trial, Mr Yeo SC challenged whether the handwriting in the Handwritten Chronology was in fact Chantal’s:
- [82]
[82] Baker, however, explained on re-examination that he was familiar with Chantal’s handwriting as he had seen many of Chantal’s notes and that her daughters would be familiar with them as well:
- [83]
[83] More importantly, Heika also explained in detail, why she was sure that the Handwritten Chronology was her mother’s handwriting:
Heika also was able to point out other notations in various documents that were not in Chantal’s handwriting. We accept her and Baker’s evidence on this score.
- [84]
[84] Although the Defendants contend that the handwriting in the Handwritten Chronology was not proved to be Chantal’s, they neither adduced independent evidence to support their claim nor called a handwriting expert to do so. We accept the evidence of Heika and Baker that the Handwritten Chronology, as well as those other notes or notations identified by them, as having been written or prepared (eg, typed) by Chantal and find that the Handwritten Chronology was written on or about 1 March 2000.
- [85]
[85] The Handwritten Chronology was a log or record by Chantal of significant events or facts that occurred in relation to the purchase of the Ethocyn Rights and assets of the Chantal Companies from 7 January 1999 to 23 Dec 1999.
(a) The first entry records: “JAN.7 1999 $800,000 wire transfer to P.F. Wong (solicitors) trust account in H.K. by CBD Pharmaceutical Corporation.” This tallies with the Hang Seng Bank Credit Advice to P F Wong (see [80] above).
(b) The second entry records: “JAN 14 1999 Legendary Trading Ltd acquires 10 kilos of Ethocyn and componentry fr Chantal Skin Care products in consideration for $100,000 [undecipherable] $775,000 loaned from P.F. Wong to Legendary.” We find this to show the transfer of monies from P F Wong to a company called Legendary Trading International Ltd (“Legendary”).
(c) The third entry records: “Jan-Sept: Legendary business of Chantal products so far to AC7/HSN $641,000 revenue.”
(d) The fourth entry records: “Sept 14, 1999 Renslade Ltd purchases for $25,000 7 kilos of Ethocyn plus componentry.”
(e) The fifth entry records: “Oct 19, 1999 Renslade purchases assets (intellectual property + inventory of 70 kilos of Ethocyn + componentry for $325,000 ($50,000 assets + $275,000 goodwill). Patents expire in 2004. Cosmetic and pharmaceutical products.”
(f) The sixth entry records: “Oct.1999 E. Cosmetics LLC, Nevada corp. do telemarketing sales of cosmetics in Los Angeles. A 100% wholly owned subsidiary of Renslade N$75,000/mo income.”
(g) The seventh entry records Chantal’s trip in November 1999 to Hong Kong with Noel Conway. There is a reference to Rio Investments “purchases, assume debt and “ ” 80% of Renslade (including E Cosmetics) and add if note for $25,000 Legendary assets (not corporation [undecipherable]). ?Note. issue $800,000 $775,000 on balance sheet.”
(h) The eighth entry records: “Dec.23, 1999 Rio Investments, Nova Derm Ltd (Victoria Medical Group Investors Ltd) acquires Renslade. Shareholder is Victoria Medical Investors 80% and Granville (20%). Noel Conway ‘mistakenly’ puts Victoria shares in his name (10 shares). Now have an assignment to Lalaine de law Cruz (who agrees to serve as ‘figure owner’ and has executed an assignment to Compagnie Carmesti-[undecipherable] S.A., a Panamanian company (presently dentist doctor friend of my father working in Philipines [sic].” We agree with Mr Bull SC when he submits that “figure owner” is Chantal’s description of someone who is a nominee owner for someone else. There are references in the evidence that at one stage of Chantal’s planning and structure, Chantal intended for one Lalaine, who was her father’s friend, to be her nominee “owner” on record. Many aspects of these notes are also corroborated by the documentary evidence, including corporate records or filings made with the respective regulatory authorities. It is also undeniable that these were all documents found by Baker in Chantal’s papers after she passed away.
(i) The remainder of the Handwritten Chronology logged as November 1999 records Chantal’s trip to Budapest to look into a laboratory and a reference to Noel Conway and the purchase of laboratory equipment from some landlord in exile in Switzerland and a reference to Wehinger.
- [86]
[86] We find the evidence shows Chantal working hard to set up corporate structures outside the USA, with the help of foreign lawyers and her new adviser, Noel Conway, who also appeared to have mistakenly issued shares in his name, as well as exploring laboratory facilities to synthesise the Ethocyn compound for the future as the German laboratory had been closed down.
- [87]
[87] We have stated at [80] above that US$800,000 was transferred from CBD Pharmaceutical to P F Wong. From the Handwritten Chronology (see [85(b)], P F Wong then transferred, in the form of a loan, US$775,000 to Legendary. The discrepancy of US$25,000 was not explained. Legendary is owned by Granville, which is in turn, controlled by Weir & Associates, Weir’s company. This is evident from the following evidence.
(a) In a facsimile dated 25 June 1999 from Weir to Mr Ken Whitney of the law firm, Ross & Whitney, Weir referred to Granville as “the same company that owns [Legendary]”. As noted above, Weir also stated that “the client is interested in acquire [sic] Renslade Holdings Ltd immediately”.
(b) Mr Ken Whitney was the sole shareholder of Renslade (NZ), until he transferred his share to Granville.
(c) Granville’s address is listed to be “c/- Weir & Associates”.
(d) In a letter dated 20 December 1999 from Simpson Grierson to Noel Conway, Granville is referred to as “a company controlled by Weir & Associates and Carrie Chan in Hong Kong”.
- [88]
[88] We find that the evidence shows a prima facie case that Legendary then provided US$750,000 to Renslade (NZ) to bid for the purchase of the Ethocyn Rights in the US Bankruptcy Proceedings. This can be seen from two documents. First, there was an email dated 20 December 1999 from Noel Conway to Chantal, where Noel Conway stated that the sum of US$775,000 transferred from P F Wong to Legendary was to ensure that “there could be an even USD 750,000 at LA at the time of the bidding in court”:
- [89]
[89] At the trial, Mr Yeo SC asserted that there was a discrepancy between the US$775,000 and the US$100,000 (as expenses) recorded in the Handwriting Chronology, against the US$750,000 in Noel Conway’s email to Chantal above. Baker explained that the difference was because Legendary used US$25,000 to “[buy] some product”. While not a complete explanation (in that it was not supported by independent documentary evidence), the Defendants did not suggest what else could the USD750,000 be used for. We find that the reference to “bidding in court” at that period was in all probability referring to the bidding of the Ethocyn Rights at the US Bankruptcy Proceedings.
- [90]
[90] Secondly, there was a facsimile from Simpson Grierson to Noel Conway dated 21 February 2000 attaching a group structure of the companies including Renslade (NZ). In that group structure, it was specifically stated that Renslade (NZ) had a debt of US$775,000 owed to the “shareholders of Granville Limited”, which as we have found at [87] above, owns Legendary:
- [92]
[92] Although Baker did not adduce evidence showing the direct transfer of funds from Legendary to Renslade (NZ), the evidence establishes, on a prima facie basis, that Chantal had provided the funds for Renslade (NZ)’s purchase of the Ethocyn Rights. The Defendants, save for highlighting arithmetical inconsistency and challenging the authenticity of the Handwritten Chronology, did not proffer any alternative explanation for the movement of funds. Further, the arithmetical inconsistencies were not, by far, of the magnitude that made them incredible or inherently unbelievable or outside of common sense. There were obviously (and there are references to these items in the documents before us) payments to lawyers, purchases of Ethocyn, as well as some earnings from sales transactions.
There were no other bidders for the Ethocyn Rights and assets of the Chantal Companies
- [93]
[93] As we observed to counsel during closing submissions, it is of some importance to note that the Ethocyn Rights and assets were not an off-the-shelf machinery or product, nor was it like a piece of land or a building. The Ethocyn Rights were comprised in intellectual property which did not have a long shelf life and the last of the patents would expire in 2004. Further, from the draft prospectus, it recites that the Chantal Companies’ laboratory in Germany had closed down. Any further exploitation involved setting up another laboratory to synthesize the Ethocyn compound. There is evidence of Chantal exploring this in November 1999. The existing stocks of Ethocyn compound had degraded somewhat, although it appears they could be salvaged. Also, to properly exploit these rights, investments had to be made. The prospectus mentions at least US$1 million in the initial investment. Further, even if a purchaser had the marketing ability and knowledge of the cosmetics industry, without someone with the knowhow to direct and supervise a laboratory to synthesize the Ethocyn compound, its true value is unascertainable and cannot be captured if there was no one to oversee the production and marketing of the Ethocyn compound. There was also a need in the longer term for further research as the last of the patents expired in 2004. We will return to these factors when we consider the statements made by Chantal to the US Bankruptcy Courts and the issues of illegality.
- [94]
[94] Although not surfaced by counsel, it appears, and we so find, that Renslade (NZ) had made a first offer, earlier on in the Chapter 11 proceedings, on behalf of “investors from Hong Kong”, of US$500,000 cash payment plus royalties to purchase the Ethocyn Rights, but this was rejected by the Creditors’ Committee. This appears in the second application by counsel for the Chantal Companies, Messrs Peitzman, Glassman & Weg, to the US Bankruptcy on 23 November 1999 for payment of their fees referred to above. In their application, they state that, after the rejection of Renslade (NZ)’s offer, they then had to work independently with the Creditors’ Committees’ investment banker, the Kriegsman Group, to find another buyer. Counsel assisted the Kriegsman Group in preparation of the “book” on the debtors and their rights and assets and spoke to several interested parties. However, no one was willing to make a written offer to purchase the Chantal Companies’ rights and assets. They state: “After several weeks went by without any new prospective purchaser appearing on the scene, [the Applicant] initiated a new negotiation with Shane Weir in Hong Kong.” It is clear to us and we find that there was no one else interested to purchase the Ethocyn Rights and assets of the Chantal Companies despite the efforts of the independent Creditors’ Committee, the Kriegsman Group and the work-out specialist, Teeple.
Transfer of the Ethocyn Rights from Renslade (NZ) to Renslade (S): who was the beneficial owner of the Ethocyn Rights?
- [95]
[95] The next issue to be determined is the beneficial owner of the Ethocyn Rights after they were transferred from Renslade (NZ) to Renslade (S). In all the documentary evidence reviewed so far, Weber is not mentioned. The documentary evidence shows Chantal liaising fairly intensely with the lawyers and advisers mentioned and this included the running of the business, dealing with the shipments of goods and products, accounts and payments and organisational issues like having a director, Carrie Chan, in Hong Kong to deal with emergencies like another company attempting to register the trademark “Ethocyn” in China. That documentary evidence extends into 3 February 2000 with tax advice from James Jan of Simpson Grierson Law and 6 March 2000 with Noel Conway trying to sort out the accounts between the various companies.
- [96]
[96] The first document featuring Weber is an email from Weber to Chantal dated 9 March 2000. It will be relevant at this stage to recapitulate the parties respective cases in the pleadings:
(a) The Estate avers that, in or around November 1999, Chantal entered into an agreement with Weber pursuant to which Weber would acquire the Ethocyn Rights from Renslade (NZ) and hold the Ethocyn Rights and any income or proceeds generated from the Ethocyn Rights on trust for Chantal. We note an earlier version of the Statement of Claim and further and better particulars furnished therein gave the date of this meeting as being in or around February 1999. However the Statement of Claim (Amendment No. 2) was amended in July 2018 to the aforesaid date. By an assignment dated 24 May 2000, Chantal procured the transfer of the Ethocyn Rights from Renslade (NZ) to Renslade (S), a company incorporated in Singapore on or around 23 May 2000. Weber was the sole shareholder of Renslade (S). By a deed dated 1 April 2002, Weber procured the transfer of the Ethocyn Rights from Renslade (S) to BCS and BCS became the trustee of the express trust. This deed was assigned shortly after BCS’s name change on 26 July 2002 and backdated to 1 April 2002.
(b) The Defendants deny that there was an agreement of any kind between Chantal and Weber for the latter to acquire and hold the Ethocyn Rights and any income and/or proceeds generated from the Ethocyn Rights on trust for Chantal. Renslade (S), a company controlled by Weber, acquired the Ethocyn Rights and assets from Renslade (NZ) for the sum of US$325,000 and the purchase price was paid for by BCS with monies that belonged to BCS and/or Weber and were not provided for by Chantal. Weber decided on the purchase because he saw an opportunity to exploit the Ethocyn Rights and assets through a business deal with Nu Skin. Weber had to transfer the Ethocyn Rights to BCS, which was an active company with several business streams, to secure the business with Nu Skin.
- [97]
[97] It is not disputed that Renslade (NZ) transferred the Ethocyn Rights to Renslade (S). As we set out the events that led to the transfer, it will be evident, and we so find, that it was Chantal who spearheaded and made key decisions in relation to the transfer of the Ethocyn Rights from Renslade (NZ) to Renslade (S). We find that Weber, contrary to the Defendants’ case as set out above, was in fact working for Chantal as her business advisor and followed her instructions in all matters. We reject Weber’s case that he purchased the Ethocyn Rights from Renslade (NZ) for his own investment.
The judgment continues past this page. Read the rest at eLitigation.